secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001193125-26-053131
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences reports Q4/FY2025 results; advances bezuclastinib NDAs in SM and GIST
--------------------------------------------------------------------------------

- SUMMIT NDA for bezuclastinib in NonAdvSM submitted Dec 2025; APEX NDA for AdvSM on track for 1H 2026.
- PEAK NDA for bezuclastinib in 2L GIST initiated under RTOR and BTD; completion expected April 2026.
- Cash, equivalents and marketable securities $900.8M as of Dec 31, 2025, sufficient into 2028.
- Net loss $102.5M in Q4 2025, $328.9M full year, vs $67.9M and $255.9M in prior year periods.
- Inducement grants: options to purchase 59,300 shares and 47,000 RSUs to 12 new employees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/0001193125-26-053131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-053131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer